Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

so the big question is whether Keytruda can do better in BTC than Imfinzi, which improved OS by 20% when added to chemo in the TOPAZ-1 trial reported in 2021. That earned Imfinzi an FDA approval ...

Keytruda is already approved for the indication, based on interim results reported in 2021 that showed a 32% ... The AI effect in pharma commercial strategy: From data to re ...

Cabozantinib is the active ingredient in two of Exelixis' three approved drugs (Cabometyx and Cometriq) and its strongest US patent covering cabozantinib’s composition of matter expires in 2030.

It’s been about one year since Amgen closed its $27.8 billion Horizon Therapeutics buyout and brought the rare disease drug ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

The surge in drug-developer IPOs in 2020 and 2021, which raised approximately ... treats several cancers and tumors. Keytruda is an astounding clinical and commercial success that is on track ...

SoFi began trading in June 2021, closing its first day at $22.65 ... Investors hope the company’s transition from clinical to commercial stage will be lucrative. ImmunityBio has navigated ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the ...

Merck & Co said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's distributor there reduces inventories amid low demand, and the U.S. drugmaker's ...